Plitidepsin - PharmaMar

Drug Profile

Plitidepsin - PharmaMar

Alternative Names: Aplidin; Aplidine; DDB; Dehydrodidemnin B

Latest Information Update: 02 Aug 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator PharmaMar
  • Class Antineoplastics; Depsipeptides
  • Mechanism of Action Apoptosis stimulants; Cell cycle inhibitors; Protein synthesis inhibitors; Vascular endothelial growth factor receptor-1 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma; Precursor cell lymphoblastic leukaemia-lymphoma
  • New Molecular Entity Yes
  • Available For Licensing Yes - Multiple myeloma; Multiple myeloma; Peripheral T-cell lymphoma

Highest Development Phases

  • Preregistration Multiple myeloma
  • Phase II Non-Hodgkin's lymphoma; T cell lymphoma
  • No development reported Liposarcoma; Malignant melanoma; Myelofibrosis; Solid tumours
  • Discontinued Leukaemia; Prostate cancer

Most Recent Events

  • 20 Jul 2018 PharmaMar terminates a phase II trial in T-cell lymphoma (Second-line therapy or greater) in Czech Republic, Italy, Spain, USA (IV) (NCT03070964) (EudraCT2015-001909-14)
  • 11 Jun 2018 PharmaMar enters into a commercialization and distribution license agreement with Pint Pharma for plitidepsin in Argentina, Bolivia, Brazil, Chile, Colombia, Ecuador, Mexico, Paraguay, Peru, Uruguay and Venezuela
  • 01 Jun 2018 PharmaMar completes a phase I trial for Multiple myeloma (Combination therapy, Second line therapy or greater) in France and Spain (NCT02100657)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top